William D Tap
Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name William D Tap as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:50 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02601209 · Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaNational Cancer Institute (NCI) · terminated · High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT02601209
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:50 UTC. The ranking covers the 200 most relevant of 64 PubMed records, and a shared surname and initials can bring in a namesake. All 64 on PubMed
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol · 2018637 citationsRCR 22.0
- 466 citationsRCR 14.5
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.N Engl J Med · 2015464 citationsRCR 12.7
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.Lancet · 2019400 citationsRCR 13.4
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.Cancer Discov · 2018376 citationsRCR 11.0
- Sorafenib for Advanced and Refractory Desmoid Tumors.N Engl J Med · 2018360 citationsRCR 13.7
- Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.J Clin Oncol · 2013352 citationsRCR 9.1
- 279 citationsRCR 7.9
- 279 citationsRCR 29.8
- 270 citationsRCR 11.2